Human stem cell research in Europe and the U.S.A.: Post Brüstle and Sherley, ethics issues and patent quagmire

Abstract

The U.S.A. does not have uniform State level laws and policies for HSCR and patent, but there are fewer complexities than in Europe. The paper measures the appropriateness of patenting HSCI and encounters many ethical debates. This article calls for a balanced IPR protection framework unique to invention that uses human biological material while finding that patent as a protection tool is not the most appropriate one for the HSCI.